|
|
Volumn 373, Issue 17, 2015, Pages 1588-1591
|
|
Reducing LDL with PCSK9 inhibitors - The clinical benefit of lipid drugs
a b,c d |
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALIROCUMAB;
ATORVASTATIN;
EVOLOCUMAB;
EZETIMIBE;
HIGH DENSITY LIPOPROTEIN CHOLESTEROL;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
LOW DENSITY LIPOPROTEIN RECEPTOR;
MEVINOLIN;
TORCETRAPIB;
TRIACYLGLYCEROL;
HYPOCHOLESTEROLEMIC AGENT;
MONOCLONAL ANTIBODY;
PCSK9 PROTEIN, HUMAN;
SERINE PROTEINASE;
CANCER RISK;
CARDIOVASCULAR DISEASE;
CAUSE OF DEATH;
CHOLESTEROL BLOOD LEVEL;
DRUG EFFICACY;
DRUG EXPOSURE;
DRUG SAFETY;
DYSLIPIDEMIA;
FAMILIAL HYPERCHOLESTEROLEMIA;
FOOD AND DRUG ADMINISTRATION;
GAIN OF FUNCTION MUTATION;
GASTROINTESTINAL DISEASE;
HUMAN;
LIPID ANALYSIS;
LIVER CELL;
LOSS OF FUNCTION MUTATION;
METABOLIC DISORDER;
NEUROLOGIC DISEASE;
NON INSULIN DEPENDENT DIABETES MELLITUS;
POSTMARKETING SURVEILLANCE;
PREVALENCE;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
REVIEW;
RISK BENEFIT ANALYSIS;
RISK FACTOR;
RISK REDUCTION;
TREATMENT OUTCOME;
TRIACYLGLYCEROL BLOOD LEVEL;
ADVISORY COMMITTEE;
ANTAGONISTS AND INHIBITORS;
BLOOD;
CARDIOVASCULAR DISEASES;
DRUG APPROVAL;
HYPERCHOLESTEROLEMIA;
UNITED STATES;
ADVISORY COMMITTEES;
ANTIBODIES, MONOCLONAL;
ANTICHOLESTEREMIC AGENTS;
CARDIOVASCULAR DISEASES;
CHOLESTEROL, LDL;
DRUG APPROVAL;
HUMANS;
HYPERCHOLESTEROLEMIA;
PROPROTEIN CONVERTASES;
RISK FACTORS;
SERINE ENDOPEPTIDASES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84944937913
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMp1508120 Document Type: Review |
|
Times cited : (123)
|
|
References (5)
|
